U.S. FDA Extends Review of Ruxolitinib Cream for Pediatric AD
The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelra, Incyte) for the treatment of children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD).